AstraZeneca 4Q13 4Q Revenues: $6.8 billion (-6%) 4Q Loss: $524 million (earnings of $1.5 billion in 4Q12) FY Revenues: $25.7 billion (-8%) FY Earnings: $2.6 billion (-60%) Comments: For FY13, AstraZeneca’s U.S. revenues fell by 9%, while Rest of World (RoW) revenues fell 4%. Crestor revenues fell by 8% in both 4Q and FY, to $1.5 billion and $5.6 billion, respectively. Onglyza reenues grew 17% in FY to $378 million, but only 6% in 4Q to $93 million. Symbicort sales were up 11% in 4Q to...